

**FOR FURTHER INFORMATION CONTACT:**

Natalie Grant, Director, Office of Human Services Emergency Preparedness and Response, 330 C St. SW, Washington, DC 20201. Telephone: 202–205–7843; Email: [Natalie.grant@acf.hhs.gov](mailto:Natalie.grant@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** OHSEPR announces the intent to award the following single-source awards:

| Recipient  | Award amount of up to |
|--|-----------------------|
| United Way Worldwide, Alexandria, VA .....   | \$75,000              |
| National Association of Social Workers, Washington, DC .....                       | 75,000                |
| American Public Human Services Association, Arlington, VA .....                    | 75,000                |
| National Association of County Human Services Administrators, Washington, DC ..... | 75,000                |

United Way supports 211, which is the most comprehensive source of information about local resources and services in the United States. United Way's 211 has demonstrated experience providing disaster-related assistance to disaster survivors. United Way's existing network of 211 agencies will provide information and referrals to evacuees from Afghanistan including repatriates eligible for temporary assistance.

NASW is the largest membership organization of professional social workers in the world. NASW has the ability to train a large number of professional social workers across the United States, including many who have provided case management and human services following an emergency. NASW will train its members on how to provide culturally competent case management and human services to evacuees from Afghanistan and ensure appropriate coordination and subject matter expertise.

APHSa is a national membership association representing state and local health and human services agencies and subject matter experts who help execute their mission. APHSA has a direct connection to a network of state and county health and human services executives with first-hand knowledge of and expertise in operating programs and delivering human services following an emergency. APHSA will educate its members on the provision of culturally appropriate human services to evacuees from Afghanistan by providing training and technical assistance.

NACHSA members represent a broad range of human services agencies throughout the United States, including

ones that provide public assistance, child care, child protective services, and adult protective services. NACHSA supports the professional development of county human services administrators, whose agencies deliver essential human services. NACHSA will educate its membership on providing culturally appropriate human services to evacuees from Afghanistan and ensure county level coordination of services.

*Statutory Authority:* Social Security Act, Title XI, Part A, Section 1113, 42 U.S. Code 1313(a)(3).

**Elizabeth Leo,**

*Senior Grants Policy Specialist, Office of Grants Policy, Office of Administration.*

[FR Doc. 2021–21418 Filed 9–28–21; 4:15 pm]

**BILLING CODE 8414-PC-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA–2021–N–0492]

**Watson Laboratories, Inc., et al.;  
Withdrawal of Approval of 36  
Abbreviated New Drug Applications;  
Correction**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of June 25, 2021. The document announced the withdrawal of approval of 36 abbreviated new drug applications (ANDAs) from multiple applicants as of July 26, 2021. The document indicated that FDA was withdrawing approval of the following ANDA, after receiving a withdrawal request from Yung Shin Pharmaceutical Ind. Co. Ltd., authorized U.S. agent, Carlsbad Technology, Inc./ Simon Law, 5922 Farnsworth Ct., Suite 101, Carlsbad, CA 92008: ANDA 065152, Cephalexin Capsules, Equivalent to (EQ) 250 milligrams (mg) base and EQ 500 mg base. Before FDA withdrew the approval of this ANDA, Yung Shin Pharmaceutical Ind. Co. Ltd. informed FDA that it did not want the approval of the ANDA withdrawn. Because Yung Shin Pharmaceutical Ind. Co. Ltd. timely requested that approval of this ANDA not be withdrawn, the approval of ANDA 065152 is still in effect.

**FOR FURTHER INFORMATION CONTACT:** Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New

Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993–0002, 240–402–6980, [Martha.Nguyen@fda.hhs.gov](mailto:Martha.Nguyen@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of Friday, June 25, 2021 (86 FR 33718), FR Doc. 2021–13593, the following correction is made:

On page 33718, in the table, the entry for ANDA 065152 is removed.

Dated: September 27, 2021.

**Lauren K. Roth,**

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2021–21371 Filed 9–30–21; 8:45 am]

**BILLING CODE 4164-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA–2019–N–3077]

**Agency Information Collection  
Activities; Proposed Collection;  
Comment Request; Obtaining  
Information To Understand Challenges  
and Opportunities Encountered by  
Compounding Outsourcing Facilities**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice requests comments on the information collection associated with FDA research in obtaining information from pharmacists and other management at outsourcing facilities and related human prescription drug compounding businesses. The research supports a comprehensive analysis of the outsourcing facility sector that informs ongoing FDA work in this area.

**DATES:** Submit either electronic or written comments on the collection of information by November 30, 2021.

**ADDRESSES:** You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before November 30, 2021. The <https://www.regulations.gov> electronic filing system will accept